Clinical Trial Update: Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase I/IIa PET imaging trial of 68GaNOTA-Anti-MMR-VHH2 for malignant solid tumors, including breast cancer and melanoma; the study status is comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Melanoma
• Solid Tumors

Drugs mentioned

• 68GaNOTA-Anti-MMR-VHH2 (Anti-MMR-VHH2)

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Malignant Solid Tumor, Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED